Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 4/20 | 0.41 |
| ▸ | BCL6 | P41182 | 2/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 10/20 | 0.34 |
| ▸ | CDK4 | P11802 | 2/20 | 0.34 |
| ▸ | CCND1 | P24385 | 2/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744156 | 0.85 | PTPN11 (0.33) | PTPN11 | |
| SCHEMBL11996276 | 0.84 | ACACB (0.36) | ACACB | |
| SCHEMBL23744157 | 0.80 | PTPN11 (0.44) | PTPN11BCL6NCOR2ACACBSCN9A | |
| SCHEMBL15247184 | 0.79 | ACACB (0.47) | PTPN11ACACBHDAC1 | |
| SCHEMBL19756416 | 0.79 | ACACB (0.41) | ACACB | |
| SCHEMBL23744770 | 0.79 | PTPN11 (0.43) | PTPN11BCL6NCOR2SCN9A | |
| SCHEMBL23744751 | 0.79 | PTPN11 (0.51) | PTPN11BCL6NCOR2ACACBSCN9A | |
| SCHEMBL23744047 | 0.79 | PTPN11 (0.51) | PTPN11BCL6NCOR2ACACBSCN9A | |
| SCHEMBL15725788 | 0.79 | PTPN11 (0.49) | PTPN11BCL6NCOR2SCN9AHDAC1 | |
| SCHEMBL24945764 | 0.79 | PTPN11 (0.43) | PTPN11BCL6NCOR2SCN9AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | PTPN11 1801/4885BCL6 4736/4885NCOR2 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.